Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 229

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Rituximab in intractable ocular lesions of Behcet’s disease; randomized single‐blind control study (pilot study)

DAVATCHI, Fereydoun, SHAMS, Hormoz, REZAIPOOR, Mozhgan, SADEGHI‐ABDOLLAHI, Bahar, SHAHRAM, Farhad, NADJI, Abdolhadi, CHAMS‐DAVATCHI, Cheyda, AKHLAGHI, Massoomeh, FAEZI, Tahereh, NADERI, Nasim · 2010 · International Journal of Rheumatic Diseases

Abstract

Background: Ocular lesions, the main morbidity of Behcet’s disease (BD), are the most difficult to treat. The aim of this study was to evaluate the efficacy of rituximab. Methods: Inclusion criteria were retinal vasculitis and edema, resistant to cytotoxic drugs. Twenty patients were randomized to a rituximab group (RG) or cytotoxic combination therapy group (CCTG). Rituximab was given in two 1000‐mg courses (15‐day interval). Subjects received methotrexate (15 mg/weekly) with prednisolone (0.5 mg/kg per day). The CCTG received pulse cyclophosphamide (1000 mg/monthly), azathioprine (2–3 mg/kg per day) and prednisolone (0.5 mg/kg per day). The primary endpoint was the overall state of patients’ eyes and the Total Adjusted Disease Activity Index (TADAI). Secondary endpoints were: visual acuity (VA), posterior uveitis (PU), and retinal vasculitis (RV). The baseline data were compared at 6 months by paired sample t‐test and analysis of variance. Results: TADAI improved significantly in the RG (t = 3.340, P = 0.009), but not in the CCTG (t = 2.241, P = 0.052). For secondary endpoints (RG/CCTG), the mean VA improved in two patients versus three (2/3), remained unchanged in 1/1, and worsened in 7/6 patients. The mean PU improved significantly in the RG (t = 3.943, P = 0.001), not in the CCTG (t = 2.371, P = 0.028). RV improved, but not statistically (t = 2.027, P = 0.057 vs. t = 1.045, P = 0.31). Edema of retina, disc and macula improved significantly in both, but much better for the RG (t = 2.781, P = 0.012 vs. t = 2.707, P = 0.014). Conclusion: Rituximab was efficient in severe ocular manifestations of BD, TADAI improved significantly after 6 months with rituximab, but not with CCT.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1756-185x.2010.01546.x

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 229

Metadata

Authors
DAVATCHI, F., SHAMS, H., REZAIPOOR, M., SADEGHI‐ABDOLLAHI, B., SHAHRAM, F., NADJI, A., CHAMS‐DAVATCHI, C., AKHLAGHI, M., FAEZI, T., & NADERI, N.
Venue
International Journal of Rheumatic Diseases
Publisher
Wiley
Published
2010-08
Volume
13
Issue
3
Pages
246-252
ISSN
  • 1756-1841 (ISSN-L)
  • 1756-185X
OpenAlex
W2142473469
Cited by
229
References
2
FWCI
15.83
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rituximab in intractable ocular lesions of Behcet’s disease; randomized single‐blind control study (pilot study). https://app.cochat.ai/papers/10.1111/j.1756-185x.2010.01546.x
The paper
DAVATCHI, F., SHAMS, H., REZAIPOOR, M., SADEGHI‐ABDOLLAHI, B., SHAHRAM, F., NADJI, A., CHAMS‐DAVATCHI, C., AKHLAGHI, M., FAEZI, T., & NADERI, N. (2010). Rituximab in intractable ocular lesions of Behcet’s disease; randomized single‐blind control study (pilot study). International Journal of Rheumatic Diseases. https://doi.org/10.1111/j.1756-185x.2010.01546.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.